


State of California—Health and Human Services Agency California Department of Public Health



OFFICE OF AIDS (OA)
AIDS Drug Assistance Program (ADAP)

Management Memorandum Memorandum Number: 2017-12

Date: December 21, 2017

TO: ADAP ENROLLMENT WORKERS

SUBJECT: ADDITION OF A NEW ANTIRETROVIRAL (ARV) MEDICATION TO THE AIDS DRUG ASSISTANCE PROGRAM (ADAP) FORMULARY

Effective December 21, 2017, dolutegravir/rilpivirine (Juluca) has been added to the ADAP formulary. Juluca is a fixed-dose tablet containing two previously approved ARV drugs, dolutegravir (Tivicay) and rilpivirine (Edurant), to treat adults with HIV-1 infections whose virus has been suppressed on a consistent treatment regimen for at least six months and who have no history of treatment failure and no known mutations associated with resistance to dolutegravir or rilpivirine. Juluca received approval from the federal Food and Drug Administration (FDA) on November 21, 2017 as a once-daily, single-tablet complete treatment regimen for HIV-1 infected patients. The two drugs that make up Juluca are already on the ADAP formulary as stand-alone medications and as ingredients of other combination drugs. The ADAP Medical Advisory Committee voted to recommend Juluca for addition to the formulary on November 29, 2017.



If you have any questions regarding the addition of this new ARV to the ADAP formulary, please contact Cynthia Reed-Aguayo, ADAP Specialist, at (916) 449-5791.

Sandra Robinson, MBA Chief, ADAP Branch

Sundia Hore

Office of AIDS